<--- Back to Details
First PageDocument Content
Genetics / Polymerase chain reaction / Duchenne muscular dystrophy / Primer / DNA sequencing / Complementary DNA / Restriction fragment length polymorphism / Exon / Molecular genetics / Biology / Molecular biology / Biochemistry
Genetics
Polymerase chain reaction
Duchenne muscular dystrophy
Primer
DNA sequencing
Complementary DNA
Restriction fragment length polymorphism
Exon
Molecular genetics
Biology
Molecular biology
Biochemistry

Volume 16 Number[removed]Nucleic Acids Research

Add to Reading List

Source URL: www.ncbi.nlm.nih.gov

Download Document from Source Website

File Size: 1,67 MB

Share Document on Facebook

Similar Documents

Microsoft Word - ASX 17_ 2 October_ ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update summary_Final

DocID: 1ulfx - View Document

19 DecemberATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update Antisense Therapeutics Limited (“ANP” or “the Company”) provides the following update on the progress of its Multiple Sclero

DocID: 1tPwS - View Document

FINAL Catabasis Pharmaceuticals Announces the Initiation of an Open-Label Extension for the MoveDMD® Trial Studying Edasalonexent (CATin Duchenne Muscular Dystrophy CAMBRIDGE, MA, July 7, 2016 – Catabasis Phar

DocID: 1t5Sx - View Document

Screening S. aureus CRISPR-Cas9 Paired Guide RNAs for Efficient Targeted Deletion in Duchenne Muscular Dystrophy Josh Tycko1, Nick Huston1, Jacqueline Robinson-Hamm2, Chris Wilson1, Charles A. Gersbach2, Patrick D. Hsu1,

DocID: 1sCDI - View Document

Research Review No. 96. Therapeutic effect of simvastatin to Duchenne Muscular Dystrophy. The Studies: The authors of this study (1) from U.S.A. note in their introduction that Duchenne muscular dystrophy (DMD) is a le

DocID: 1rWwv - View Document